After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for BridgeBio Pharma Inc. (BBIO) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $14.57. The BridgeBio Pharma Inc. has recorded 238,962 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed BridgeBio Pharma Announces Pricing of Public Offering of Common Stock.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Stocks Info
BridgeBio Pharma Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $14.57 and fluctuated between $14.67 as its day high and $14.01 as its day low. The current market capitalization of BridgeBio Pharma Inc. is $2.42B. A total of 2.24 million shares were traded on the day, compared to an average of 2.55M shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, BBIO has seen 4 BUY and 12 SELL insider trades, representing the acquisition of 103,289 and the disposition of 661,251 shares. Over the last 12 months, there were 17 BUYs and 26 SELLs from insiders. Insiders purchased 426,098 shares during that period but sold 837,981.
In the most recent transaction, Kumar Neil sold 120,000 shares of BBIO for 10.96 per share on Mar 03. After the transaction, the CEO and President now owns 1,252,722 company shares. In a previous transaction on Mar 03, STEPHENSON BRIAN C sold 62,692 shares at 10.96 per share. BBIO shares that Secretary, Treasurer & CFO owns now total 156,837.
Among the insiders who sold shares, Kumar Neil disposed of 44,798 shares on Feb 17 at a per-share price of $12.70. This resulted in the CEO and President holding 4,813,197 shares of BBIO after the transaction. In another insider transaction, STEPHENSON BRIAN C sold 17,717 shares at $12.70 per share on Feb 17. Company shares held by the Secretary, Treasurer & CFO now total 219,529.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for BBIO in the last 3 months, the mean price target is $25.63 with high estimates of $32.00 and low estimates of $18.00. In terms of 52-week highs and lows, BBIO has a high of $19.94 and a low of $4.98.
As of this writing, BBIO has an earnings estimate of -$0.85 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.71 per share and a lower estimate of -$1.14. The company reported an EPS of -$0.07 in the last quarter, which was 88.90% higher than expectations of -$0.63.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Overweight with a score of 4.89. A total of 8 analysts rated the stock as Buy while 1 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.
